drugset / Trial / NCT00002045

A Prospective Double-Blind Study of Retrovir in Early HIV Infection

NCT00002045

Completed Glaxo Wellcome
Double-blindTreatment

Summary

To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zidovudine Small molecule